FDA OKs Low-Dose Colchicine for Broad CV Indication at AshTip Solution.

AshTip NewsLetter |The US Food and Drug Administration has approved the anti-inflammatory drug colchicine 0.5 mg tablets (Lodoco) as the first specific anti-inflammatory drug demonstrated to reduce the risk for myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death

Medscape

FDA OKs Low-Dose Colchicine for Broad CV Indication

FDA OKs Low-Dose Colchicine for Broad CV Indication

The US Food and Drug Administration has approved the anti-inflammatory drug colchicine 0.5 mg tablets (Lodoco) as the first specific anti-inflammatory drug demonstrated to reduce the risk for myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.